Professional Experience
Gregory B. Sephton, Ph.D. has over 15 years experience in all aspects of patent litigation and has played leading roles in litigating and trying complex chemical, pharmaceutical and biotechnology litigations, as well as advising clients on patent strategy, as well as advising on ex parte and inter partes patent reexaminations.
Professional Activities
American Intellectual Property Law Association; New York Intellectual Property Law Association
Representative Matters
· Warner Chilcott against Actavis Elizabeth, Heritage, Impax, Mylan and Sandoz on a patent covering Doryx® brand doxycycline hyclate tablets.
· Sanofi-Aventis against Barr, Mutual, Synthon and Watson on a patent relating to formulations of zolpidem Ambien CR® (zolpidem), a sleeping aid.
· Novartis against Barr, Watson and Dr. Reddy'son patents concerning the Alzheimer's drug Exelon® (rivastigmine)
· KOS Pharmaceuticals against Bar on patents covering KOS' Niaspan® anti-cholesterol drugs.
· AstraZeneca in multi-district litigation involving the anti-ulcer drug, PRILOSEC® (omeprazole)
· Bausch & Lomb in Bausch & Lomb v. Alcon and Bausch & Lomb v. Allergan(contact lens care products containing proteolytic enzymes and antimicrobial agents)
· Emory University in Emory University v. Glaxo-Wellcome and Emory University v. BioChem Pharma and Glaxo-Wellcome (anti-AIDS and anti-hepatitis pharmaceuticals)
· The Liposome Company in The Regents of the University of Texas v. The Liposome Company involving anti-fungal pharmaceuticals
Representative Cases
Warner Chilcott Laboratories Ireland Limited, et al., v. Mylan Pharmaceuticals Inc. and Mylan Inc.
D.N.J. 2011
In re Omeprazole Patent Litigation
S.D.N.Y. 2002
Events
Recent US Case Law Developments Affecting Primary and Secondary Pharma Patents
C5's 7th Annual Pharma Patent Lifecycles Conference
June 27, 2008